The Pituitary TGFβ1 System As a Novel Target for the Treatment of Resistant Prolactinomas

Overview

Journal J Endocrinol

Specialty Endocrinology

Date 2015 Dec 25

PMID 26698564

Citations 21

Authors

M Victoria Recouvreux

M Andrea Camilletti

Daniel B Rifkin

Graciela Diaz-Torga

Affiliations

Soon will be listed here.

Abstract

Prolactinomas are the most frequently observed pituitary adenomas and most of them respond well to conventional treatment with dopamine agonists (DAs). However, a subset of prolactinomas fails to respond to such therapies and is considered as DA-resistant prolactinomas (DARPs). New therapeutic approaches are necessary for these tumors. Transforming growth factor β1 (TGFβ1) is a known inhibitor of lactotroph cell proliferation and prolactin secretion, and it partly mediates dopamine inhibitory action. TGFβ1 is secreted to the extracellular matrix as an inactive latent complex, and its bioavailability is tightly regulated by different components of the TGFβ1 system including latent binding proteins, local activators (thrombospondin-1, matrix metalloproteases, integrins, among others), and TGFβ receptors. Pituitary TGFβ1 activity and the expression of different components of the TGFβ1 system are regulated by dopamine and estradiol. Prolactinomas (animal models and humans) present reduced TGFβ1 activity as well as reduced expression of several components of the TGFβ1 system. Therefore, restoration of TGFβ1 inhibitory activity represents a novel therapeutic approach to bypass dopamine action in DARPs. The aim of this review is to summarize the large literature supporting TGFβ1 important role as a local modulator of pituitary lactotroph function and to provide recent evidence of the restoration of TGFβ1 activity as an effective treatment in experimental prolactinomas.

Citing Articles

Prolactinoma: Navigating the Dual Challenge of Side Effects and Treatment Strategies - A Comprehensive Review.

Yogeeta F, Rauf S, Devi M, Imran K, Ahmed R, Aruwani P Ann Med Surg (Lond). 2024; 86(8):4613-4623.

PMID: 39118737 PMC: 11305738. DOI: 10.1097/MS9.0000000000002308.

Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.

Dzialach L, Sobolewska J, Zak Z, Respondek W, Witek P Front Endocrinol (Lausanne). 2024; 15:1338345.

PMID: 38370355 PMC: 10870150. DOI: 10.3389/fendo.2024.1338345.

Prognostic Biomarkers in Pituitary Tumours: A Systematic Review.

Papadimitriou E, Chatzellis E, Dimitriadi A, Kaltsas G, Theocharis S, Alexandraki K touchREV Endocrinol. 2024; 19(2):42-53.

PMID: 38187082 PMC: 10769480. DOI: 10.17925/EE.2023.19.2.12.

Revealing Sexual Dimorphism in Prolactin Regulation From Early Postnatal Development to Adulthood in Murine Models.

Abeledo-Machado A, Pena-Zanoni M, Bornancini D, Diaz-Torga G J Endocr Soc. 2023; 8(1):bvad146.

PMID: 38045876 PMC: 10690727. DOI: 10.1210/jendso/bvad146.

Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways.

Serioli S, Agostini L, Pietrantoni A, Valeri F, Costanza F, Chiloiro S Int J Mol Sci. 2023; 24(21).

PMID: 37958702 PMC: 10650665. DOI: 10.3390/ijms242115719.

References

Farrell W . Pituitary tumours: findings from whole genome analyses. Endocr Relat Cancer. 2006; 13(3):707-16. DOI: 10.1677/erc.1.01131. View

Wong A, Eloy J, Couldwell W, Liu J . Update on prolactinomas. Part 2: Treatment and management strategies. J Clin Neurosci. 2015; 22(10):1568-74. DOI: 10.1016/j.jocn.2015.03.059. View

McCormack A, Wass J, Grossman A . Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest. 2011; 41(10):1133-48. DOI: 10.1111/j.1365-2362.2011.02520.x. View

Akhurst R, Hata A . Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012; 11(10):790-811. PMC: 3520610. DOI: 10.1038/nrd3810. View

Fernandez A, Karavitaki N, Wass J . Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2009; 72(3):377-82. DOI: 10.1111/j.1365-2265.2009.03667.x. View

Delgrange E, Trouillas J, Maiter D, Donckier J, TOURNIAIRE J . Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997; 82(7):2102-7. DOI: 10.1210/jcem.82.7.4088. View

Derynck R, Akhurst R . Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol. 2007; 9(9):1000-4. DOI: 10.1038/ncb434. View

Shi Y, Massague J . Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003; 113(6):685-700. DOI: 10.1016/s0092-8674(03)00432-x. View

Liu J, Patel J, Eloy J . The role of temozolomide in the treatment of aggressive pituitary tumors. J Clin Neurosci. 2015; 22(6):923-9. DOI: 10.1016/j.jocn.2014.12.007. View

10.

Daly A, Tichomirowa M, Beckers A . The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009; 23(5):543-54. DOI: 10.1016/j.beem.2009.05.008. View

11.

Cao L, Gao H, Gui S, Bai G, Lu R, Wang F . Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models. J Neurooncol. 2014; 116(3):523-31. DOI: 10.1007/s11060-013-1351-8. View

12.

Diaz-Torga G, Feierstein C, Libertun C, Gelman D, Kelly M, Low M . Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. Endocrinology. 2002; 143(4):1270-9. DOI: 10.1210/endo.143.4.8750. View

13.

Melmed S . Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011; 7(5):257-66. DOI: 10.1038/nrendo.2011.40. View

14.

Burns G, Sarkar D . Transforming growth factor beta 1-like immunoreactivity in the pituitary gland of the rat: effect of estrogen. Endocrinology. 1993; 133(3):1444-9. DOI: 10.1210/endo.133.3.8365375. View

15.

Pohlers D, Brenmoehl J, Loffler I, Muller C, Leipner C, Schultze-Mosgau S . TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta. 2009; 1792(8):746-56. DOI: 10.1016/j.bbadis.2009.06.004. View

16.

Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H . Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab. 1999; 84(9):3268-76. DOI: 10.1210/jcem.84.9.5962. View

17.

Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A . Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas. J Neuroendocrinol. 1996; 8(10):737-46. DOI: 10.1046/j.1365-2826.1996.04902.x. View

18.

Cristina C, Diaz-Torga G, Baldi A, GONGORA A, Rubinstein M, Low M . Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology. 2005; 146(7):2952-62. DOI: 10.1210/en.2004-1445. View

19.

Zaldivar V, Magri M, Zarate S, Jaita G, Eijo G, Radl D . Estradiol increases the Bax/Bcl-2 ratio and induces apoptosis in the anterior pituitary gland. Neuroendocrinology. 2009; 90(3):292-300. DOI: 10.1159/000235618. View

20.

Shimazu S, Shimatsu A, Yamada S, Inoshita N, Nagamura Y, Usui T . Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. Eur J Endocrinol. 2011; 166(3):383-90. DOI: 10.1530/EJE-11-0656. View